GE HealthCare Technologies Inc. (GEHC): A Bull Case Theory

We came across a bullish thesis on GE HealthCare Technologies Inc. on Guardian Research’s Substack. In this article, we will summarize the bulls’ thesis on GEHC. GE HealthCare Technologies Inc.'s share was trading at $83.86 as of February 23rd. GEHC’s trailing and forward P/E were 15.74 and 16.69 respectively according to Yahoo Finance.

Wichy/Shutterstock.com

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. GE HealthCare Technologies Inc. (GEHC) presents a compelling investment case supported by a strengthening balance sheet, durable cash generation, and significant valuation upside following its separation from General Electric. The company entered public markets with elevated leverage but has steadily improved its financial position through disciplined debt reduction, strong capital markets access, and consistent free cash flow of $1.5–1.7 billion annually, providing ample capacity to fund the $2.3 billion Intelerad acquisition while maintaining conservative net leverage near 1.5x EBITDA.

Cash conversion remains a core strength, with operating cash flow of $2.0 billion and normalized near-100% earnings-to-cash conversion once temporary tariff headwinds are excluded, reinforcing confidence in the durability of future earnings growth. Despite these fundamentals, GEHC trades around 16x forward earnings, a steep discount to medtech peers and closest comparable Siemens Healthineers, reflecting lingering conglomerate stigma, China concerns, and tariff-depressed margins.

Valuation analysis across DCF and sum-of-the-parts frameworks supports a near-term fair value of $105–120 and a longer-term trajectory toward $200 per share as margins expand, recurring revenue exceeds 60%, and EPS compounds toward $8.50–9.50 by 2030. This dual engine of earnings growth and multiple re-rating creates asymmetric returns with limited downside, even under conservative assumptions.

Technical indicators reinforce the opportunity, with strong support around $75–80 and constructive institutional positioning, while analyst targets from firms such as Goldman Sachs, Stifel, and Evercore ISI remain below intrinsic value, leaving room for upgrades. Historical spinoff dynamics, including the trajectory of GE Vernova, suggest further re-rating potential as execution continues. Overall, GEHC represents a high-quality medtech franchise transitioning toward a recurring-revenue model, where the market is pricing a mature equipment manufacturer while the underlying reality is a multi-year compounder with substantial upside.